Distinct benefit from crizotinib in lung cancer patients carrying distinct ALK translocations: is fluorescent hybridization in situ testing still sufficient to guide clinical decisions?

被引：2
作者：
Mitiushkina, Natalia V. [1 ]
Imyanitov, Evgeny N. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] NN Petrov Inst Oncol, Leningradskaya Str 68, St Petersburg 197758, Russia
[2] St Petersburg Pediat Med Univ, St Petersburg 194100, Russia
[3] II Mechnikov North Western Med Univ, St Petersburg 191015, Russia
[4] City Canc Ctr, St Petersburg 197758, Russia
[5] St Petersburg State Univ, St Petersburg 199034, Russia
来源：
TRANSLATIONAL CANCER RESEARCH | 2016年 / 5卷
基金：
俄罗斯科学基金会;
关键词：
GROWTH-FACTOR RECEPTOR; MOLECULAR-PATHOLOGY; ANAPLASTIC LYMPHOMA; FUSION VARIANTS; C-MET; CELL; KINASE; MECHANISMS; INHIBITOR; EGFR;
D O I：
10.21037/tcr.2016.12.69
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1393 / S1395
页数：3
相关论文
共 25 条
[1]   Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs [J].
Bayliss, Richard ;
Choi, Jene ;
Fennell, Dean A. ;
Fry, Andrew M. ;
Richards, Mark W. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2016, 73 (06) :1209-1224
[2]   Testing for ROS1 in non-small cell lung cancer: a review with recommendations [J].
Bubendorf, Lukas ;
Buettner, Reinhard ;
Al-Dayel, Fouad ;
Dietel, Manfred ;
Elmberger, Goran ;
Kerr, Keith ;
Lopez-Rios, Fernando ;
Marchetti, Antonio ;
Oz, Buge ;
Pauwels, Patrick ;
Penault-Llorca, Frederique ;
Rossi, Giulio ;
Ryska, Ales ;
Thunnissen, Erik .
VIRCHOWS ARCHIV, 2016, 469 (05) :489-503
[3]   Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma [J].
Christensen, James G. ;
Zou, Helen Y. ;
Arango, Maria E. ;
Li, Qiuhua ;
Lee, Joseph H. ;
McDonnell, Scott R. ;
Yamazaki, Shinji ;
Alton, Gordon R. ;
Mroczkowski, Barbara ;
Los, Gerrit .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3314-3322
[4]   Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study [J].
Gadgeel, Shirish M. ;
Gandhi, Leena ;
Riely, Gregory J. ;
Chiappori, Alberto A. ;
West, Howard L. ;
Azada, Michele C. ;
Morcos, Peter N. ;
Lee, Ruey-Min ;
Garcia, Linta ;
Yu, Li ;
Boisserie, Frederic ;
Di Laurenzio, Laura ;
Golding, Sophie ;
Sato, Jotaro ;
Yokoyama, Shumpei ;
Tanaka, Tomohiro ;
Ou, Sai-Hong Ignatius .
LANCET ONCOLOGY, 2014, 15 (10) :1119-1128
[5]   The role of the ALK receptor in cancer biology [J].
Hallberg, B. ;
Palmer, R. H. .
ANNALS OF ONCOLOGY, 2016, 27 :4-15
[6]   Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants [J].
Heuckmann, Johannes M. ;
Balke-Want, Hyatt ;
Malchers, Florian ;
Peifer, Martin ;
Sos, Martin L. ;
Koker, Mirjam ;
Meder, Lydia ;
Lovly, Christine M. ;
Heukamp, Lukas C. ;
Pao, William ;
Kueppers, Ralf ;
Thomas, Roman K. .
CLINICAL CANCER RESEARCH, 2012, 18 (17) :4682-4690
[7]   Novel ALK fusion partners in lung cancer [J].
Iyevleva, Aglaya G. ;
Raskin, Grigory A. ;
Tiurin, Vladislav I. ;
Sokolenko, Anna P. ;
Mitiushkina, Natalia V. ;
Aleksakhina, Svetlana N. ;
Garifullina, Aigul R. ;
Strelkova, Tatiana N. ;
Merkulov, Valery O. ;
Ivantsov, Alexandr O. ;
Kuligina, Ekatherina Sh. ;
Pozharisski, Kazimir M. ;
Togo, Alexandr V. ;
Imyanitov, Evgeny N. .
CANCER LETTERS, 2015, 362 (01) :116-121
[8]   Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer [J].
Kerr, K. M. ;
Bubendorf, L. ;
Edelman, M. J. ;
Marchetti, A. ;
Mok, T. ;
Novello, S. ;
O'Byrne, K. ;
Stahel, R. ;
Peters, S. ;
Felip, E. .
ANNALS OF ONCOLOGY, 2014, 25 (09) :1681-1690
[9]  
Kim Hyojin, 2014, Korean J Pathol, V48, P1, DOI 10.4132/KoreanJPathol.2014.48.1.1
[10]   Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy [J].
Kobayashi, Yoshihisa ;
Mitsudomi, Tetsuya .
CANCER SCIENCE, 2016, 107 (09) :1179-1186
123